Revance Therapeutics (RVNC) Tops Q3 EPS by 6c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. MRNA
7. CSX
8. LVS
9. QGEN
10. SPCX

Go back to Revance Therapeutics (RVNC) Tops Q3 EPS by 6c

Revance Releases Third Quarter 2018 Results

November 1, 2018 4:05 PM EDT

- Chief Financial Officer Toby Schilke and Interim Head of Commercial - Aesthetics & Therapeutics Dustin Sjuts to assume roles on November 5 -

NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced results for the third quarter ended September 30, 2018.

Recent Company Highlights and Upcoming Milestones for DaxibotulinumtoxinA for Injection (RT002)

Plans to report the SAKURA 3 open-label, long-term safety study of RT002 for the treatment of... More